MTOR and Miyoshi myopathy: LGH447 has been tested in MM and AML models and has shown significant activity as a pan-PIM kinase inhibitor according to a study by Garcia et al.45 At first, mutations were identified in murine T-cell lines showing expression of PIM1, 2 and 3 kinases belonging to the larger PIM kinase family.46 Preclinical studies showed evidence that LGH447 was active in PIM2-dependent MM cell lines by inhibiting proliferation, mTOR-C1 signaling and inhibiting tumor growth in mouse and subcutaneous xenograft models.